(Press-News.org) The current clinical trial process in the United States is on shaky ground. In this era of personalized medicine, as diseases are increasingly defined by specific genetic and biologic markers and treatments are tailored accordingly, patient populations for new therapies grow smaller and smaller. Coupled with skyrocketing costs and expanding regulatory requirements, the completion of trials that are essential in bringing new and effective therapies to patients is no easy task.
Change is needed.
Today, in the New England Journal of Medicine, a group of renowned researchers from around the world propose a new model to revitalize the research engine in this country – collaborative clinical trials. They believe collaborative trials – in which different companies team up and share the costs to test new therapies or devices – will ensure safe and effective treatments become available more quickly and at a lower cost than they do today.
"The process of approving drugs for clinical use is progressively reaching an impasse in certain areas, and the problem will only be made worse with discoveries relating to personalized medicine, because there will be more drugs but smaller patient populations to test them in," said Daniel Ryan, M.D., chairman of the Department of Pathology and Laboratory Medicine at the University of Rochester Medical Center. "This is a way to restructure the system that will help us bring more good drugs forward for patient care."
A collaborative clinical trial could involve similar therapies from different companies, such as two drugs to lower blood pressure. Or, they could test a combination of different therapies from different companies, with each therapy designed to target a unique pathway or mechanisms involved in a more complex disease, like cancer.
There are many advantages to collaborative trials, including easier patient enrollment, especially when a disease affects a small number of patients, or a therapy can only be tested in a small subgroup of patients with a specific genetic mutation. Competition for patients can slow the enrollment process and ultimately the time it takes to get results.
"Rather than two or three separate clinical trials competing for patients, things can get done faster by companies coming together and conducting a single trial," said Arthur J. Moss, M.D., a cardiologist at the Medical Center. "You can also use a single control group of patients, which cuts the number of participants needed and subsequently time and costs."
Another major advantage is the ability to directly compare several new therapies, or new versus old therapies, since they are all being tested in the same patient population, with the same set of rules, measuring the same set of outcomes.
"Treatment A may work compared to control in one trial, and treatment B may also work compared to control in another trial, but we wind up with no information on how to compare A and B," said Charles Francis, M.D., a professor in the Departments of Medicine and Pathology and Laboratory Medicine at the Medical Center.
"In the end, if we can come up with a more robust trial design that actually compares the effectiveness of different treatments, we are right in line with President Obama's healthcare initiative, which calls for providers and researchers to look at the things we're doing and study whether or not they are effective," added Ryan.
Today, large clinical trials are extremely expensive to carry out, as the FDA requires much better documentation, increasing quality control and longer follow-up periods than in the past. Many trials are international, spanning the U.S., Europe, Japan and other countries. The number of people needed to carry out an international trial involving thousands of patients for several years is a substantial cost in-and-of-itself.
Scientists have conducted studies with collaborative elements in cardiology and asthma, and some are beginning in multiple myeloma and Alzheimer's disease, though the approach has yet to catch on broadly across all areas of research.
Researchers acknowledge that there are limitations to collaborative studies. New regulations from the Food and Drug Administration may be needed to guide trials of competing products, since companies are often in a race to make their product available first. Antitrust and patent issues associated with such collaborative trials will require negotiation and possibly new legislation, as well.
"We want to bring new options to patients faster and at less cost, but we also want to do the best science," said Moss. "While the trial system might be improved in many ways, we think collaborative clinical trials are a strong option that should be considered."
"I don't anticipate that every company will start launching cooperative trials, but I think it will happen in certain clinical situations where this type of study seems especially well suited," said Ryan. "Ultimately, people need to see it as a good business proposition, that there is a competitive advantage to doing it this way."
INFORMATION:
Drs. Moss, Ryan and Francis wrote the Perspective piece on collaborative clinical trials featured in today's New England Journal of Medicine on behalf of all the members of the Multicenter Research Group. Formed in 1980, the group includes a range of clinical investigators who plan and conduct research, pooling resources and experience with the ultimate goal of improving patient care.
Members of the Multicenter Research Group include: Arthur J. Moss, M.D. (Chair), Rochester, NY; Jesaia Benhorin, M.D., Tel Aviv, Israel; J. Thomas Bigger, Jr. M.D., New York, NY; Poul Erik Bloch Thomsen, M.D., Copenhagen, Denmark; Monty Bodenheimer, New York, NY; Mary W. Brown, M.S., Rochester, NY; Robert Case, M.D., New York, NY; Edward M. Dwyer, M.D., Newark, NJ; Charles W. Francis, M.D., Rochester, NY; John Gillespie, M.D., Buffalo, NY; Robert E. Goldstein, M.D., Bethesda, MD; Henry Greenberg, M.D., New York, NY; Mark C. Haigney, M.D., Bethesda, MD; Helmut U. Klein, M.D., Rochester, NY; Ronald Krone, M.D., St. Louis, MO; Edgar Lichstein, M.D., New York, NY; Emanuela Locati, M.D., Milan, Italy; Frank Marcus, M.D., Tucson, AZ; David Oakes, M.D., Rochester, NY; Daniel Ryan, M.D., Rochester, NY; Wojciech Zareba, M.D., Ph.D., Rochester, NY.
END
Immigration debates are often fueled more by rhetoric than by actual facts and figures. Fortunately, the non-partisan Pew Research Center (which does not take positions on policy issues) offers objective statistics on immigration in their annual survey of national and state trends in immigration, as published by the Pew Hispanic Center.
The national highlights from Pew's 2010 immigration report include:
- Unauthorized immigrants make up about 3.7 percent of the nation's population --approximately 11.2 million persons. That number is statistically unchanged from last ...
ANN ARBOR, Mich. — Researchers at the University of Michigan Comprehensive Cancer Center have identified a potential target to treat an aggressive type of prostate cancer. The target, a gene called SPINK1, could be to prostate cancer what HER2 has become for breast cancer.
Like HER2, SPINK1 occurs in only a small subset of prostate cancers – about 10 percent. But the gene is an ideal target for a monoclonal antibody, the same type of drug as Herceptin, which is aimed at HER2 and has dramatically improved treatment for this aggressive type of breast cancer.
"Since SPINK1 ...
PROVIDENCE, R.I. [Brown University] — What makes a man? His clothes? His car? His choice of scotch? The real answer, says Brown University biologist Erica Larschan, is the newly understood activity of a protein complex that, like a genetic power tool, gives enzymes on the X-chromosome an extra boost to increase gene expression. The process is described in the March 3, 2011, issue of the journal Nature.
Women have two X-chromosomes in their genomes while males have an X and a Y. Gender is defined by that difference, but for men to live, the genetic imbalance must be remedied. ...
The recent sentencing of a 28-year-old Gaston County man for multiple sex offenses, including second-degree sex offense of a child and one count of indecent liberties with a child, reveals the severe consequences that a conviction or guilty plea can bring. Marcus Stephen Archer pleaded guilty to two of six counts and faces up to ten years in prison as well as lifetime registration as a sex offender. He will also be required to submit to satellite monitoring after his release from prison.
Archer admits not remembering the events due to heavy drug use during the time the ...
With the steep decline in populations of many animal species, from frogs and fish to tigers, some scientists have warned that Earth is on the brink of a mass extinction like those that occurred only five times before during the past 540 million years.
Each of these 'Big Five' saw three-quarters or more of all animal species go extinct.
In a study to be published in the March 3 issue of the journal Nature, University of California, Berkeley, paleobiologists assess where mammals and other species stand today in terms of possible extinction, compared with the past 540 ...
Thousands, if not millions of people worldwide, use Tylenol or Tylenol-related products with the active ingredient Acetaminophen each week. The over-the-counter drug is labelled as an effective treatment method to reduce a fever and relieve minor aches and pains. While it is considered safe by medical professionals in some circles, new information about the risks of prolonged use, overuse and even common use have raised red flags for medical professionals.
It is well-known that excessive use of Acetaminophen (may be abbreviated as APAP on drug labels), such as an accidental ...
Physicists and mathematicians from the University of Santiago de Compostela in Spain are putting paid to the theory that two languages cannot co-exist in one society.
Analysing the pattern of populations speaking Castilian, the most common language spoken in Spain, and Galician, a language spoken in Galicia, the North West autonomous community of Spain, the researchers have used mathematical models to show that levels of bilingualism in a stable population can lead to the steady co-existence of two languages.
The research, published today, Thursday 3 March 2011, in ...
(March 2, 2011—Toronto, ON and Helsinki, Finland) Dr. Andras Nagy's laboratory at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital and Dr. Timo Otonkoski's laboratory at Biomedicum Stem Cell Center (University of Helsinki), as well as collaborators in Europe and Canada have identified genetic abnormalities associated with reprogramming adult cells to induced pluripotent stem (iPS) cells. The findings give researchers new insights into the reprogramming process, and will help make future applications of stem cell creation and subsequent use safer.
The study ...
Atlanta SEO company Cardinal Web Solutions takes a proactive approach in its client's SEO and Internet marketing campaigns. While the recent announcement from Google of an updated search engine algorithm has shaken up the SEO industry, Cardinal Web Solutions sees these changes as a reinforcement of the company's focus on quality.
Cardinal Web Solutions is a leading Atlanta SEO company that provides search engine optimization and internet marketing.
In February, Matt Cutts of Google described on the company's blog what he called a "pretty big algorithmic improvement" ...
Ordinary human cells reprogrammed as induced pluripotent stem cells (hiPSCs) may ultimately revolutionize personalized medicine by creating new and diverse therapies unique to individual patients. But important and unanswered questions have persisted about the safety of these cells, in particular whether their genetic material is altered during the reprogramming process.
A new study – published in the March 3 issue of the journal Nature and led by scientists at the University of California, San Diego in collaboration with other leading stem cell research groups – finds ...
